Zarar Azaltma Yaklaşımları: Steril Enjeksiyon Ekipmanı, Nalokson, Düşük Eşikli Hizmet Modelleri ve Damgalamayı Azaltma

Yazarlar

Hümeyra Yılmaz
https://orcid.org/0000-0002-0952-9889

Referanslar

Strang J, McDonald R, Campbell G, et al. Take-home naloxone for the emergency interim management of opioid overdose: the public health application of an emergency medicine. Drugs. 2019;79(13):1395-1418. doi: 10.1007/s40265-019-01154-5.

World Health Organization. Opioid overdose. Geneva: WHO; updated August 29, 2025 [Online]. https://www.who.int/news-room/fact-sheets/detail/opioid-overdose (Erişim tarihi: 13.08.2026).

Jakubowski A, Fox A. Defining low-threshold buprenorphine treatment. Journal of Addiction Medicine. 2020;14(2):95-98. doi: 10.1097/ADM.0000000000000555.

Bielenberg J, Swisher G, Lembke A, Haug NA. A systematic review of stigma interventions for providers who treat patients with substance use disorders. Journal of Substance Abuse Treatment. 2021;131:108486. doi: 10.1016/j.jsat.2021.108486.

European Union Drugs Agency (EUDA). Harm reduction – the current situation in Europe (European Drug Report 2026). Lisbon: EUDA 2026. [Online]. https://www.euda.europa.eu/publications/european-drug-report/2026/harm-reduction_en (Erişim tarihi: 19.08.2026).

Hawk M, Coulter RWS, Egan JE, et al. Harm reduction principles for healthcare settings. Harm Reduction Journal. 2017;14(1):70. doi: 10.1186/s12954-017-0196-4.

Merrall EL, Kariminia A, Binswanger IA, et al. Meta-analysis of drug-related deaths soon after release from prison. Addiction. 2010;105(9):1545-1554. doi: 10.1111/j.1360-0443.2010.02990.x.

Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. doi: 10.1136/bmj.j1550.

Santo T Jr, Clark B, Hickman M, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiatry. 2021;78(9):979-993. doi: 10.1001/jamapsychiatry.2021.0976.

Platt L, Minozzi S, Reed J, et al. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database of Systematic Reviews. 2017;9:CD012021. doi: 10.1002/14651858.CD012021.pub2.

MacArthur GJ, Minozzi S, Martin N, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012;345:e5945. doi: 10.1136/bmj.e5945.

European Centre for Disease Prevention and Control; European Monitoring Centre for Drugs and Drug Addiction. Prevention and control of infectious diseases among people who inject drugs: 2023 update. Stockholm: ECDC; Lisbon: EMCDDA; 2023. https://www.ecdc.europa.eu/en/publications-data/prevention-and-control-infectious-diseases-among-people-who-inject-drugs-2023 (Erişim tarihi: 19.08.2026).

Strang J, Darke S, Hall W, et al. Heroin overdose: the case for take-home naloxone. BMJ. 1996;312(7044):1435. doi: 10.1136/bmj.312.7044.1435.

World Health Organization. Community management of opioid overdose. Geneva: WHO; 2014.

https://www.who.int/publications/i/item/9789241548816 (Erişim tarihi: 17.08.2026).

McDonald R, Lorch U, Woodward J, et al. Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: phase I healthy volunteer study. Addiction. 2018;113(3):484-493.

doi: 10.1111/add.14033.

Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346:f174. doi: 10.1136/bmj.f174.

Giglio RE, Li G, DiMaggio CJ. Effectiveness of bystander naloxone administration and overdose education programs: a meta-analysis. Injury Epidemiology. 2015;2(1):10. doi:10.1186/s40621-015-0041-8.

McDonald R, Strang J. Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction. 2016;111(7):1177-87. doi: 10.1111/add.13326.

Moustaqim-Barrette A, Dhillon D, Justin Ng, et al. Take-home naloxone programs for suspected opioid overdose in community settings: a scoping umbrella review. BMC Public Health. 2021;21(1):597. doi: 10.1186/s12889-021-10497-2.

Fischer LS, Asher A, Stein R, et al. Effectiveness of naloxone distribution in community settings to reduce opioid overdose deaths among people who use drugs: a systematic review and meta-analysis. BMC Public Health. 2025;25:1135. doi: 10.1186/s12889-025-22210-8.

Moustaqim-Barrette A, Papamihali K, Williams S, et al. Adverse events related to bystander naloxone administration in cases of suspected opioid overdose in British Columbia: An observational study. PLoS One. 2021;16(10):e0259126. doi: 10.1371/journal.pone.0259126.

Payne ER, Stancliff S, Rowe K, et al. Comparison of administration of 8-milligram and 4-milligram intranasal naloxone by law enforcement during response to suspected opioid overdose - New York, March 2022-August 2023. Morbidity and Mortality Weekly Report (MMWR). 2024;73:110-113. doi: 10.15585/mmwr.mm7305a4.

Strang J. Take-home naloxone and the prevention of deaths from heroin overdose: pursuing strong science, fuller understanding, greater impact. European Addiction Research. 2022;28(3):161-175. doi: 10.1159/000519939.

Chan RRD, Yakiwchuk EM, Halpape K. Take-home naloxone access and use among older adults living with pain: a scoping review. The Canadian Journal of Hospital Pharmacy. 2024;77(1):e3506. doi: 10.4212/cjhp.3506.

Marshall BDL, Milloy MJ, Wood E, et al. Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. Lancet. 2011;377(9775):1429-1437. doi: 10.1016/S0140-6736(10)62353-7.

Gariépy G, Prowse RKM, Plouffe R, et al. Supervised consumption sites and population-level overdose mortality: a systematic review of recent evidence, 2016-2024. Health Promotion and Chronic Disease Prevention Canada. 2025;45(9):357-366. doi: 10.24095/hpcdp.45.9.02.

Maghsoudi N, Tanguay J, Scarfone K, et al. Drug checking services for people who use drugs: a systematic review. Addiction. 2022;117(3):532-544. doi: 10.1111/add.15734.

Lee JD, Vocci F, Fiellin DA. Unobserved "home" induction onto buprenorphine. Journal of Addiction Medicine. 2014;8(5):299-308. doi: 10.1097/ADM.0000000000000059.

Carroll KM, Weiss RD. The role of behavioral interventions in buprenorphine maintenance treatment: a review. American Journal of Psychiatry. 2017;174(8):738-747. doi: 10.1176/appi.ajp.2016.16070792.

Alford DP, LaBelle CT, Richardson JM, et al. Treating homeless opioid dependent patients with buprenorphine in an office-based setting. Journal of General Internal Medicine. 2007;22(2):171-176. doi: 10.1007/s11606-006-0023-1.

Langendam MW, van Brussel GH, Coutinho RA, et al. The impact of harm-reduction-based methadone treatment on mortality among heroin users. American Journal of Public Health. 2001;91(5):774-780. doi: 10.2105/ajph.91.5.774.

Ahamad K, Hayashi K, Nguyen P, et al. Effect of low-threshold methadone maintenance therapy for people who inject drugs on HIV incidence in Vancouver, BC, Canada: an observational cohort study. Lancet HIV. 2015;2(10):e445-450. doi: 10.1016/S2352-3018(15)00129-0.

Nolan S, Hayashi K, Milloy MJ, Kerr T, Dong H, Lima VD, et al. The impact of low-threshold methadone maintenance treatment on mortality in a Canadian setting. Drug and Alcohol Dependence. 2015;156:57-61. doi: 10.1016/j.drugalcdep.2015.08.037.

van Boekel LC, Brouwers EPM, van Weeghel J, et al. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. Drug and Alcohol Dependence. 2013;131(1-2):23-35. doi: 10.1016/j.drugalcdep.2013.02.018.

Sibley AL, Colston DC, Go VF. Interventions to reduce self-stigma in people who use drugs: a systematic review. Journal of Substance Use and Addiction Treatment. 2024;159:209284. doi: 10.1016/j.josat.2023.209284.

Corrigan PW, Rao D. On the self-stigma of mental illness: stages, disclosure, and strategies for change. Canadian Journal of Psychiatry. 2012;57(8):464-469. doi: 10.1177/070674371205700804.

Rivera AV, DeCuir J, Crawford ND, et al. Internalized stigma and sterile syringe use among people who inject drugs in New York City, 2010-2012. Drug and Alcohol Dependence. 2014;144:259-264. doi: 10.1016/j.drugalcdep.2014.09.778.

Luoma JB, Kulesza M, Hayes SC, et al. Stigma predicts residential treatment length for substance use disorder. American Journal of Drug and Alcohol Abuse. 2014;40(3):206-212. doi: 10.3109/00952990.2014.901337.

Kelly JF, Westerhoff CM. Does it matter how we refer to individuals with substance-related conditions? A randomized study of two commonly used terms. International Journal of Drug Policy. 2010;21(3):202-207. doi: 10.1016/j.drugpo.2009.10.010.

Livingston JD, Milne T, Fang ML, et al. The effectiveness of interventions for reducing stigma related to substance use disorders: a systematic review. Addiction. 2012;107(1):39-50. doi: 10.1111/j.1360-0443.2011.03601.x.

Luoma JB, Kohlenberg BS, Hayes SC, et al. Slow and steady wins the race: a randomized clinical trial of acceptance and commitment therapy targeting shame in substance use disorders. Journal of Consulting and Clinical Psychology. 2012;80(1):43-53. doi: 10.1037/a0026070.

Karakaya I, Sacakli G, Bilici R, et al. The pathway to care of patients with SUD who presented at addiction treatment centers (AMATEM) in Turkey. Journal of Ethnicity in Substance Abuse. 2022;21(1):55-69. doi: 10.1080/15332640.2019.1704959.

Türkiye Uyuşturucu ve Uyuşturucu Bağımlılığı İzleme Merkezi (TUBİM). Türkiye Uyuşturucu Raporu 2025. Ankara: Emniyet Genel Müdürlüğü Narkotik Suçlarla Mücadele Başkanlığı; 2025. https://www.narkotik.pol.tr/kurumlar/narkotik.pol.tr/Duyurular/2025/10/2025-Uyusturucu-Raporu.pdf (Erişim tarihi: 21.08.2026).

Yayınlanan

18 Kasım 2026

Lisans

Lisans